Erastin suppresses the malignant phenotype of hepatoma cells by hindering the O‐GlcNAcylation of c‐Jun, which further represses protein expression, transcriptional activity, and nuclear accumulation of c‐Jun. Here, JUN is linked to hepatocellular carcinoma.